Business Standard

Monday, December 23, 2024 | 10:43 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

stake sale
Premium

stake sale

Sohini DasB Dasarath Reddy Mumbai
Dr Reddy's Laboratories (DRL) has entered into a definitive agreement with Wockhardt to acquire select divisions of its branded generics business in India, Nepal, Sri Lanka, Bhutan and Maldives, and a manufacturing plant for Rs 1,850 crore. 

The business is valued at 3.8 times the annualised revenue. As a part of the deal, a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines would be transferred to DRL, along with related business assets and liabilities, contracts, permits, intellectual properties, employees, and marketing, sales and distribution of the same (in India, Nepal, Bhutan,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in